Gerresheimer

Activities: Drug Delivery

Trending Articles

  1. Payload cleaning and analytics: overcoming the challenges of payload cleaning and analytics in ADC manufacturing 29 January 2026 | Virtual
  2. Grifols receives US FDA approval for new fibrinogen concentrate: FESILTY (fibrinogen, human-chmt) The fibrinogen concentrate complements Grifols’ bleeding management portfolio, expanding therapeutic options for patients
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Integrating responsible AI into ESG strategies Today, artificial intelligence (AI) is changing the way businesses operate, but there’s no denying that it presents both opportunities and risks
  4. ten23 health QC lab to support commercial product testing for US customer following FDA approvals This pivotal regulatory milestone enables FDA-compliant release and stability testing for injectable drug products throughout the clinical and commercial phases, in addition to...
  5. From data to decisions: applying criticality and failure probability in process risk mitigation This article presents an exploration of how structured, data-based methods enhance quality control, optimise specifications and improve process robustness throughout the...

Upcoming event

From powder to granules: a deep dive into wet granulation methods

14 January 2026 | Virtual See all

Related Content

Drug Delivery

Science based targets initiative confirms CO2e reduction targets

Targets align with the Paris Agreement to limit global warming to 1.5 °C. Reduction of Scope 1 and 2 emissions by 52% by 2030 and reduction of the intensity of selected Scope 3 emissions by 64% by 2034

Gerresheimer appoints Uwe Röhrhoff as interim CEO

Dietmar Siemssen to step down after seven years, completing new Management Board formation
Manufacturing

Gerresheimer adjusts 2025 guidance amid slower market growth

Transformation program launched to boost performance and free cash flow
Design & Build

Gerresheimer boosts Wertheim site with new production facility

The new production hall will focus on RTF vials and innovative EZ-fill Smart packaging platform, with a total investment volume of around EUR €30 million
Manufacturing

Gerresheimer and Portal Instruments team up to commercialise PRIME Nexus reusable autoinjector

Gerresheimer and Portal Instruments are joining forces to develop and manufacture the PRIME Nexus syringe-based, reusable, connected autoinjector platform, offering pharmaceutical companies an end-to-end solution for delivering chronic disease therapies
Sustainability

Gerresheimer improves Rating Result and is once again awarded EcoVadis Gold

Gerresheimer, among the top 4% of all rated companies, whose rating reaches a new high with 78 out of 100 points, ranking among the top 1% of the industry underlines consistent implementation of the sustainability strategy
Drug Delivery

Achim Schalk to join the Gerresheimer Management Board

Responsibility for the Moulded Glass, Tubular Glass, and Syringe Systems business units
Subscribe now